Netarsudil (AR-13324) has been evaluated across numerous clinical trials ranging from Early Phase 1 to Phase 4, primarily targeting open-angle glaucoma and ocular hypertension, alongside secondary conditions such as normal tension glaucoma, proliferative vitreoretinopathy, and Fuchs' endothelial dystrophy. Conducted by both industry sponsors, such as Aerie Pharmaceuticals and Alcon Research, and academic institutions including the Mayo Clinic and Massachusetts Eye and Ear Infirmary, these studies reflect diverse recruitment statuses ranging from actively recruiting and completed to not yet recruiting, active not recruiting, or terminated.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT07588152 | RECRUITING | Glaucoma; Ocular Hypertension |
Indiana University |
2026-06-05 | PHASE4 |
| NCT07325240 | RECRUITING | Open Angle Glaucoma; Ocular Hypertension |
Mayo Clinic |
2025-11-21 | PHASE4 |
| NCT07465913 | RECRUITING | Glaucoma |
Eye Centers of Southeast Texas |
2026-05-14 | PHASE4 |
| NCT04401982 | RECRUITING | Ocular Hypertension; Suspect Glaucoma |
University of Maryland, Baltimore |
2026-07-02 | PHASE4 |
| NCT07048886 | NOT_YET_RECRUITING | Primary Open Angle Glaucoma |
Center for Sight Las Vegas |
2025-07-15 | PHASE4 |
| NCT07209410 | RECRUITING | Glaucoma |
Insight Eyecare Specialties, Inc. dba Vision Source Eyecare, |
2025-11-01 | PHASE4 |
| NCT06033703 | RECRUITING | Rhegmatogenous Retinal Detachment; Proliferative Vitreoretinopathy |
Massachusetts Eye and Ear Infirmary |
2025-01-14 | PHASE1; PHASE2 |
| NCT06865144 | ACTIVE_NOT_RECRUITING | Primary Open Angle Glaucoma or Ocular Hypertension |
East Coast Institute for Research |
2025-06-27 | PHASE4 |
| NCT07082816 | COMPLETED | Ocular Hypertension; Open Angle Glaucoma |
Alcon Research |
2025-09-02 | PHASE3 |
| NCT06960629 | COMPLETED | Pseudophakic Bullous Keratopathy; Glaucoma |
University Hospital Dubrava |
2025-01-01 | PHASE2; PHASE3 |
| NCT06441643 | COMPLETED | Open Angle Glaucoma; Ocular Hypertension |
Alcon Research |
2024-09-04 | PHASE2 |
| NCT06449352 | COMPLETED | Normal Tension Glaucoma |
Westlake Eye Specialists |
2024-06-13 | PHASE4 |
| NCT05660447 | UNKNOWN | Rhegmatogenous Retinal Detachment; Proliferative Vitreoretinopathy |
Wills Eye |
2023-02-06 | PHASE2; PHASE3 |
| NCT06394973 | COMPLETED | Glaucoma; Ocular Hypertension |
Laboratoires Thea |
2024-08-05 | PHASE2 |
| NCT06033703 | Not yet recruiting | Rhegmatogenous Retinal Detachment|Proliferative Vitreoretinopathy |
Massachusetts Eye and Ear Infirmary |
2024-02 | Phase 1|Phase 2 |
| NCT04752020 | COMPLETED | Fuchs' Endothelial Dystrophy |
Massachusetts Eye and Ear Infirmary |
2021-03-28 | EARLY_PHASE1 |
| NCT05283395 | COMPLETED | Glaucoma |
Aerie Pharmaceuticals |
2022-03-28 | PHASE4 |
| NCT04064918 | WITHDRAWN | OAG - Open-Angle Glaucoma; OHT - Ocular Hypertension |
University of California, San Diego |
2021-12 | |
| NCT04981886 | UNKNOWN | Normal Tension Glaucoma |
Salus University |
2021-08 | PHASE4 |
| NCT03971357 | TERMINATED | Fuchs' Endothelial Dystrophy |
Price Vision Group |
2019-07-22 | PHASE2; PHASE3 |
| NCT04498169 | COMPLETED | Corneal Edema |
Aerie Pharmaceuticals |
2020-09-17 | PHASE2 |
| NCT04620135 | COMPLETED | Primary Open Angle Glaucoma; Ocular Hypertension |
Aerie Pharmaceuticals |
2020-11-30 | PHASE3 |
| NCT04234932 | UNKNOWN | Glaucoma, Open-Angle |
University of the Incarnate Word |
2020-01-06 | EARLY_PHASE1 |
| NCT04057053 | COMPLETED | Fuchs' Endothelial Dystrophy; Cataract |
Massachusetts Eye and Ear Infirmary |
2018-10-02 | EARLY_PHASE1 |
| NCT03284853 | COMPLETED | Open Angle Glaucoma; Ocular Hypertension |
Aerie Pharmaceuticals |
2017-09-05 | PHASE3 |
| NCT04051463 | COMPLETED | Fuchs Endothelial Dystrophy |
Price Vision Group |
2019-08-05 | PHASE2; PHASE3 |
| NCT03844945 | COMPLETED | Open Angle Glaucoma; Ocular Hypertension |
Aerie Pharmaceuticals |
2019-03-19 | PHASE2 |
| NCT03808688 | COMPLETED | Glaucoma, Open-Angle; Ocular Hypertension |
Aerie Pharmaceuticals |
2018-12-27 | PHASE4 |
| NCT03248037 | COMPLETED | Fuchs' Endothelial Dystrophy; Bullous Keratopathy |
Cornea Research Foundation of America |
2017-09-05 | PHASE3 |
| NCT03310580 | COMPLETED | Primary Open Angle Glaucoma or Ocular Hypertension |
Aerie Pharmaceuticals |
2017-11-15 | PHASE2 |
| NCT03233308 | COMPLETED | Primary Open Angle Glaucoma or Ocular Hypertension |
Aerie Pharmaceuticals |
2017-10-20 | PHASE2 |
| NCT02558400 | COMPLETED | Open-angle Glaucoma; Ocular Hypertension |
Aerie Pharmaceuticals |
2015-09-18 | PHASE3 |
| NCT02674854 | COMPLETED | Open-angle Glaucoma; Ocular Hypertension |
Aerie Pharmaceuticals |
2016-02 | PHASE3 |
| NCT02246764 | COMPLETED | Ocular Hypertension; Glaucoma |
Aerie Pharmaceuticals |
2014-09 | PHASE3 |
| NCT02558374 | COMPLETED | Open-angle Glaucoma; Ocular Hypertension |
Aerie Pharmaceuticals |
2015-09 | PHASE3 |
| NCT02874846 | COMPLETED | Ocular Hypertension; Open Angle Glaucoma |
Aerie Pharmaceuticals |
2016-07 | PHASE2 |
| NCT02406287 | COMPLETED | Healthy Subjects |
Aerie Pharmaceuticals |
2015-04 | PHASE1 |
| NCT02207621 | COMPLETED | Ocular Hypertension; Open-angle Glaucoma |
Aerie Pharmaceuticals |
2014-07 | PHASE3 |
| NCT02207491 | COMPLETED | Ocular Hypertension; Open-angle Glaucoma |
Aerie Pharmaceuticals |
2014-07 | PHASE3 |
| NCT02057575 | COMPLETED | Open Angle Glaucoma; Ocular Hypertension |
Aerie Pharmaceuticals |
2014-01 | PHASE2 |
| NCT01997879 | COMPLETED | Healthy |
Aerie Pharmaceuticals |
2013-11 | PHASE1 |
| NCT01731002 | COMPLETED | Ocular Hypertension; Open Angle Glaucoma |
Aerie Pharmaceuticals |
2012-11 | PHASE2 |
| NCT01528787 | COMPLETED | Ocular Hypertension; Open Angle Glaucoma |
Aerie Pharmaceuticals |
2012-03 | PHASE2 |
(data from https://clinicaltrials.gov, updated on 2026-06-11)
Check the
Netarsudil (AR-13324) 2HCl
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
- Netarsudil (AR-13324) 2HCl Solubility in DMSO
- Netarsudil (AR-13324) 2HCl Stock Solution
- Netarsudil (AR-13324) 2HCl Storage
- Netarsudil (AR-13324) 2HCl Stability
- Netarsudil (AR-13324) 2HCl Molecular Weight
- Netarsudil (AR-13324) 2HCl SMILES
- Netarsudil (AR-13324) 2HCl CAS Number
- Netarsudil (AR-13324) 2HCl Chemical Structure (2D and 3D)
- Netarsudil (AR-13324) 2HCl SDS｜MSDS
Note: Technical data last updated: Sep 1, 2026.